Redpin Therapeutics
We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
$62—93m (Dealroom.co estimates Mar 2020.)
New York City New York (HQ)
Authorizing premium user...